Higher investments in R&D activities, focus on new product launches in international market and loss of exclusivity may turn into strong presence in highly regulated markets like US and Europe.
Original Article: Indian pharma cos secure 138 ANDA approvals from US FDA during first half ended June 2017
NEXT ARTICLE